EMA approves two drugs against severe Covid-19 course

The European Medicines Agency (EMA) has two drugs for a severe course of Covid-19 approved. Regkirona and Ronapreve significantly reduce the chance that corona patients will end up in hospital due to or die from Covid-19, the EMA writes. The European Commission has yet to confirm the approval of the drugs, but the advice of the drug agency is expected to be adopted.

Regkirona and Ronapreve can be given as an injection or infusion to corona patients from the age of 12, who do not yet need extra oxygen, but who are at risk of rapidly deteriorating. Ronapreve also has a preventive effect: tests with the drug showed that users were less susceptible to the corona virus.

The drugs are the first approved drugs with monoclonal antibodies. These are artificial antibodies that work, for example, for people who do not build up their own immunity. Regkirona and Ronapreve are the first corona drugs to be approved by the drug agency since June 2020, when remdesivir received a positive review. That drug also reduces the risk of a serious course of Covid-19.